NEW YORK, Jan. 29, 2019 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or
"the Company") announced today that it will host a key opinion
leader (KOL) breakfast on targeted conditioning for bone marrow
transplant (BMT) and CAR-T from 8:00 AM to
9:30 AM EST on Thursday, February 7th, in
New York City.
The event will feature a presentation by KOL Sergio Giralt, MD, Chief of Adult BMT,
Memorial Sloan Kettering Cancer Center, who will discuss the
potential of targeted conditioning with ARCs or Antibody
Radiation-Conjugates in conjunction with BMT or Bone Marrow
Transplant for patients ineligible or underserved by current
conditioning regimens. Dr. Giralt's presentation will highlight an
initial safety and feasibility analysis of data from Actinium's
pivotal Iomab-B Phase 3 SIERRA trial, which were presented in an
oral presentation at the 60th American Society of Hematology (ASH)
Annual Meeting in December 2018. Dr.
Giralt will be available at the conclusion of the event to answer
any questions from the audience.
In addition, members of the Actinium management team will
discuss how the Company is applying its ARCs for targeted
conditioning in patients prior to CAR-T with the goal of
eliminating the need for chemotherapy conditioning regimens like
Flu/Cy (Fludarabine and Cyclophosphamide). Finally, management will
introduce their AWE or Antibody Warhead Enabling technology
platform that has enabled combination trials with Venetoclax, a
bio-better of J&J's darzalex, and a research collaboration with
Astellas Pharma, Inc.
This event is intended for institutional investors, sell-side
analysts, and business development professionals only and they are
requested to RSVP Click Here. For those who are unable to
attend in person, a live webcast and replay will be accessible via
the link Click Here.
About Dr. Sergio
Giralt
Dr. Giralt, MD, Chief of Adult BMT, Memorial
Sloan Kettering Cancer Center; Chair, Myeloma Service; and a
board-certified hematologist/oncologist whose clinical practice and
research focus on stem cell transplantation for patients with blood
disorders. Previously, Dr. Giralt was Deputy Chair of the
Department of Stem Cell Transplantation and Cellular Therapies at
the University of Texas MD Anderson
Cancer Center.
Dr. Giralt and his colleagues pioneered the use of
reduced-intensity conditioning regimens for older or more
debilitated patients with blood cancers, and are currently using
and studying T cell depletion techniques to dramatically reduce the
risk of graft-versus-host disease, a serious complication of donor
stem cell transplantation. Dr. Giralt's clinical and research
activities include stem cell transplantation for patients with
blood disorders and improving treatments for older patients who
have acute and chronic leukemia. He has published and presented
extensively on these topics. Additionally, Dr. Giralt has served as
the principal investigator for a number of clinical trials that
examine new treatment approaches for multiple myeloma and other
blood cancers that aim to reduce symptom burden and improve
treatment tolerability.
Dr. Giralt received his medical degree from Universidad Central
de Venezuela. He completed his
residency at Good Samaritan Hospital and his fellowship at The
University of Texas MD Anderson Cancer
Center. Dr. Giralt is Professor of Medicine at Weill Cornell
Medical College and the Chief Attending Physician of the Adult Bone
Marrow Transplant Service in the Department of Medicine at Memorial
Sloan Kettering Cancer Center in New York
City. In addition, he is the Melvin Berlin Family Chair in
Myeloma Research.
About Actinium Pharmaceuticals, Inc.
Actinium
Pharmaceuticals Inc. is focused on improving patient access and
outcomes to cellular therapies such as bone marrow transplant (BMT)
and CAR-T with its proprietary, chemotherapy free, targeted
conditioning technology. Actinium is the only company with a
multi-disease, multi-target, drug development pipeline focused on
targeted conditioning. Its targeted conditioning technology is
enabled by ARCs or Antibody Radio-Conjugates that combine the
targeting ability of monoclonal antibodies with the cell killing
ability of radioisotopes. Actinium's pipeline of clinical-stage
targeted conditioning ARCs target the antigens CD45 and CD33 for
patients with a broad range of hematologic malignancies including
acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS).
Iomab-B, Actinium's lead targeted conditioning product
candidate, is currently enrolling patients in the pivotal Phase 3
SIERRA trial in patients age 55 or older, with active, relapsed or
refractory AML. Iodine-131 apamistamab (Iomab-B), combines the
anti-CD45 monoclonal antibody labeled with iodine-131 for
myeloablation prior to a bone marrow transplant. CD45 is expressed
on leukemia, lymphoma and normal immune cells. Iomab-B has been
studied in over 500 patients in 10 clinical trials in numerous
hematologic diseases. Actinium's Iomab-ACT program is an expansion
of its CD45 program that is intended to be a universal, chemo-free
solution for targeted lymphodepletion prior to CAR-T. Through
targeted lymphodepletion, the Iomab-ACT program is expected to
improve CAR-T cell expansion, reduce CAR-T related toxicities and
expand patient access to CAR-T treatment and potentially other
adoptive cell therapies. Due to its lower payload dose,
lymphodepletion with the Iomab-ACT program can be accomplished
through a single outpatient infusion. Actinium intends to advance
its Iomab-ACT program with CAR-T focused collaborators from
academia and industry.
Actinium's pipeline also includes a potentially best-in-class
CD33 program with its ARC comprised of the anti-CD33 antibody
lintuzumab labeled with the alpha-particle emitter actinium-225.
Its CD33 program is currently being studied in multiple Phase 1
clinical trials for targeting conditioning, in combinations and as
a therapeutic in multiple diseases and indications including AML,
MDS and MM.
Actinium is also developing its proprietary AWE or Antibody
Warhead Enabling technology platform which utilizes radioisotopes
including iodine-131 and the highly differentiated actinium-225
coupled with antibodies to target a variety of antigens that are
expressed in hematological and solid tumor cancers. The AWE
technology enables Actinium's internal pipeline and with the
radioisotope Actinium-225 is being utilized in a collaborative
research partnership with Astellas Pharma, Inc. Actinium's clinical
programs and AWE technology platform are covered by a portfolio of
over 75 patents covering composition of matter, formulations,
methods of use and also methods of manufacturing the radioisotope
Actinium-225 in a cyclotron.
More information is available at www.actiniumpharma.com and our
Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals,
Inc.
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
View original
content:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-host-key-opinion-leader-breakfast-on-targeted-conditioning-for-bone-marrow-transplant-and-car-t-on-february-7th-300785622.html
SOURCE Actinium Pharmaceuticals, Inc.